Based on the client's genetic nutrient risk profile and supported by clinical references, here is a structured supplementation protocol:
Personalised Supplementation Protocol
Based on Genetic Nutrient Risk Profile
𦴠1. Calcium
Genes flagged: CASR, GCKR, GATA3, DGKH, DGKD, CYP24A1
Risk: High β bone health, muscle function, cardiac rhythm
| Parameter | Recommendation |
|---|
| Supplement form | Calcium citrate (preferred β better absorbed, less GI upset, doesn't require stomach acid) |
| Dose | 500 mg elemental calcium twice daily (total 1,000β1,200 mg/day from all sources) |
| Timing | Split doses with meals β never take >500 mg at once (absorption ceiling) |
| Co-factor | Pair with Vitamin D3 (1,000β2,000 IU/day) to enhance intestinal absorption |
| Monitoring | Serum calcium every 6 months; adjust if hypercalcemia occurs |
| Food sources | Dairy, fortified plant milks, sesame seeds, ragi (finger millet), leafy greens |
Clinical basis: "Calcium supplementation consistent with general population guidelines (1,000β1,200 mg daily from all sources)" β Sabiston Textbook of Surgery
π§ 2. Vitamin B6 (Pyridoxine)
Gene flagged: NBPF3
Risk: High β mood, cognition, neurotransmitter synthesis
| Parameter | Recommendation |
|---|
| Supplement form | Pyridoxal-5-phosphate (P5P) β the active, bioavailable form |
| Dose | 25β50 mg/day |
| Timing | Morning with food |
| Upper limit | Do NOT exceed 100 mg/day long-term β high doses cause peripheral neuropathy |
| Monitoring | Plasma PLP (pyridoxal phosphate) levels; watch for neuropathy symptoms |
| Food sources | Poultry, chickpeas, banana, fortified cereals, sunflower seeds |
Clinical basis: "Low-dose vitamin B6 supplementation (50β100 mg)" used in neuropathy prevention; B6 toxicity is a risk at high doses β Bradley and Daroff's Neurology in Clinical Practice
π 3. Omega-3 Fatty Acids
Genes flagged: FADS1, FADS2
Risk: High requirement β reduced endogenous conversion of ALA β EPA/DHA
| Parameter | Recommendation |
|---|
| Supplement form | High-purity fish oil (triglyceride form preferred) or algae-based DHA/EPA (vegan option) |
| Dose | 2,000β3,000 mg combined EPA + DHA per day |
| Timing | With a fat-containing meal (improves absorption); split into 2 doses |
| Rationale | FADS1/FADS2 variants impair conversion efficiency β pre-formed EPA/DHA bypasses the bottleneck |
| Monitoring | Omega-3 index blood test (target: >8%); lipid panel every 6β12 months |
| Food sources | Fatty fish (salmon, mackerel, sardines) 2β3Γ/week; walnuts, flaxseed (limited benefit due to FADS variants) |
βοΈ 4. Omega-6 Reduction Strategy
Genes flagged: FADS1, FADS3
Risk: Elevated pro-inflammatory omega-6 conversion
This is primarily dietary modification, not supplementation:
| Action | Detail |
|---|
| Avoid | Sunflower oil, corn oil, soybean oil, processed/fried foods |
| Use instead | Olive oil, avocado oil, coconut oil (in moderation) |
| Target ratio | Dietary omega-6:omega-3 ratio below 4:1 |
| Synergy | The omega-3 supplementation above will actively help correct this imbalance |
π΄ 5. Vitamin B12
Genes flagged: CUBN, FUT2, TCN1, FUT6, CD320, TCN2
Risk: Above-average β absorption impairment (intrinsic factor pathway, transcobalamin transport)
| Parameter | Recommendation |
|---|
| Supplement form | Methylcobalamin (preferred over cyanocobalamin β active form, better tissue retention) |
| Dose | 1,000 mcg/day orally β high-dose oral bypasses IF-dependent absorption (~1% passive absorption) |
| Timing | Morning, sublingual or dissolvable tablet for better mucosal absorption |
| Monitoring | Serum B12 + homocysteine + MMA (methylmalonic acid) every 6β12 months |
| Food sources | Meat, eggs, dairy, fortified nutritional yeast (for vegetarians) |
Clinical basis: "High-dose oral B12 works even in the absence of intrinsic factor because ~1% of B12 uptake is passive" β Biochemistry, Lippincott Illustrated Reviews
βοΈ 6. Vitamin D3
Context: Lower genetic risk of deficiency, but environmental factors (indoor lifestyle, pollution, darker skin) significantly elevate population-level deficiency risk (50β94% in India)
| Parameter | Recommendation |
|---|
| Supplement form | Cholecalciferol (D3) |
| Dose | 1,000β2,000 IU/day maintenance; if serum 25(OH)D <20 ng/mL, load with 60,000 IU/week for 8 weeks |
| Timing | With a fat-containing meal (fat-soluble) |
| Synergy | Essential co-factor for calcium absorption (above) |
| Monitoring | Serum 25(OH)D every 6 months; target 40β60 ng/mL |
β
What This Client Does NOT Need
| Nutrient | Status | Action |
|---|
| Vitamin A | Genetically protected (BCO1) | Balanced diet only; avoid mega-dosing β risk of toxicity |
| Vitamin C | Optimal genetics (SLC23A1) | Balanced diet; no supplementation needed |
| Iron | No overload risk, no deficiency risk | Standard dietary intake; avoid supplementation unless bloodwork indicates otherwise |
π Priority Supplement Stack Summary
| Priority | Supplement | Form | Daily Dose |
|---|
| βββ | Omega-3 (EPA+DHA) | Fish oil / Algae oil | 2,000β3,000 mg |
| βββ | Vitamin B12 | Methylcobalamin | 1,000 mcg |
| ββ | Calcium | Calcium citrate | 500 mg Γ2 |
| ββ | Vitamin D3 | Cholecalciferol | 1,000β2,000 IU |
| ββ | Vitamin B6 | Pyridoxal-5-Phosphate (P5P) | 25β50 mg |
Important notes:
- All supplementation should be reviewed by a registered dietitian or physician before initiating
- Genetic risk indicates predisposition, not certainty β baseline blood tests should confirm deficiencies before high-dose protocols
- Supplements should complement, not replace, a whole-food diet
- Retest key markers (calcium, B12, 25(OH)D, omega-3 index) at 3β6 months to assess response and adjust dosing